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Although the intracellular role of ATP as an energy source
was well established soon after its discovery, the role of
ATP as an extracellular signalling molecule was slow to be
accepted. There were early descriptions of the extracellular
actions of ATP on the heart and blood vessels [1] and the
nervous system [2]. Release of ATP from sensory nerve
collaterals during antidromic stimulation was demonstrated
[3] and in 1970, ATP was proposed as a neurotransmitter in
non-adrenergic, non-cholinergic autonomic nerves and the
term Fpurinergic` established [4]. However, it was not
generally accepted until both ionotropic and metabotropic
receptors for ATP were cloned and characterised in the
early to mid 1990s (see [5]). There followed a rapid
explosion of interest in purinergic signalling in a wide
range of biological systems, including nervous, cardiovas-
cular, respiratory, immune, urinogenital, musculo-skeletal
and gastrointestinal systems and the special senses (see [6])
and studies of changes in expression of receptors during
development, ageing and disease (see [7]). There is strong
recent emphasis on the therapeutic potential of purinergic
agents (see [8]). My international colleagues and I, to-
gether with Springer, feel that it is timely to launch a
journal devoted to purinergic signalling to bring together
the diverse molecular, physiological, biochemical, phar-
macological and clinical studies of different systems and to
encourage bridges to be built between basic science,
clinical medicine and industrial development.
The new journal was announced at the Purines 2004
Meeting in Chapel Hill and we are most grateful to Ken
Harden and his organising team to allow us to approach
the many outstanding participants that were invited to
speak at the Meeting, to contribute papers in the inaugural
issues.
Geoffrey Burnstock
Editor-in-Chief
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